BerandaBEIGF • OTCMKTS
add
Beigene Ltd
Tutup sebelumnya
$15,95
Rentang tahun
$13,68 - $20,61
Kapitalisasi pasar
32,11 M USD
Rasio P/E
-
Hasil dividen
-
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 1,12 M | 48,64% |
Biaya operasional | 941,18 jt | 5,98% |
Laba bersih | 1,27 jt | 100,51% |
Margin laba bersih | 0,11 | 100,33% |
Penghasilan per saham | 0,01 | 100,41% |
EBITDA | 42,73 jt | 118,01% |
Tarif pajak efektif | 93,92% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 2,52 M | -9,91% |
Total aset | 5,84 M | 3,07% |
Total liabilitas | 2,34 M | 1,50% |
Total ekuitas | 3,50 M | — |
Saham yang beredar | 107,95 jt | — |
Harga terhadap nilai buku | 0,49 | — |
Tingkat pengembalian aset | 0,47% | — |
Tingkat pengembalian modal | 0,62% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Laba bersih | 1,27 jt | 100,51% |
Kas dari operasi | 44,08 jt | 114,29% |
Kas dari investasi | -121,94 jt | 41,89% |
Kas dari pembiayaan | -33,78 jt | -120,81% |
Perubahan kas bersih | -108,16 jt | 71,43% |
Arus kas bebas | -145,31 jt | 62,90% |
Tentang
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Didirikan
28 Okt 2010
Situs
Karyawan
11.000
